PURPOSE: The aim of this study was to determine the prognostic significance of lymph node micrometastases in patients with breast cancer. PATIENTS AND METHODS: Between September 2000 and January 2004, 3,369 patients with breast cancer were included in a prospective cohort. According to their lymph node status, they were classified in the following four groups: 2,383 were node negative, 107 had isolated tumor cells, 123 had micrometastases, and 756 had macrometastases. Median follow-up time was 52 months. Kaplan-Meier estimates and the multivariate Cox proportional hazard regression model were used to analyze survival. RESULTS: Five-year cause-specific and event-free survival rates were lower for patients with micrometastases (pN1mi) than for node-negative (pN0) patients (94.1% v 96.9% and 79.6% v 87.1%, respectively; P = .020 and P = .032, respectively). There was no significant survival difference between node-negative patients and those with isolated tumor cells. The overall survival of pN1mi and pN0 patients did not differ. CONCLUSION: This study demonstrates a worse prognosis for patients with micrometastases than for node-negative patients.
PURPOSE: The aim of this study was to determine the prognostic significance of lymph node micrometastases in patients with breast cancer. PATIENTS AND METHODS: Between September 2000 and January 2004, 3,369 patients with breast cancer were included in a prospective cohort. According to their lymph node status, they were classified in the following four groups: 2,383 were node negative, 107 had isolated tumor cells, 123 had micrometastases, and 756 had macrometastases. Median follow-up time was 52 months. Kaplan-Meier estimates and the multivariate Cox proportional hazard regression model were used to analyze survival. RESULTS: Five-year cause-specific and event-free survival rates were lower for patients with micrometastases (pN1mi) than for node-negative (pN0) patients (94.1% v 96.9% and 79.6% v 87.1%, respectively; P = .020 and P = .032, respectively). There was no significant survival difference between node-negative patients and those with isolated tumor cells. The overall survival of pN1mi and pN0 patients did not differ. CONCLUSION: This study demonstrates a worse prognosis for patients with micrometastases than for node-negative patients.
Authors: Caryn M St Clair; Ane Gerda Z Eriksson; Jennifer A Ducie; Elizabeth L Jewell; Kaled M Alektiar; Martee L Hensley; Robert A Soslow; Nadeem R Abu-Rustum; Mario M Leitao Journal: Ann Surg Oncol Date: 2015-12-29 Impact factor: 5.344
Authors: Rohan Rao; Jasmine A McDonald; Emily S Barrett; Patricia Greenberg; Dede K Teteh; Susanne B Montgomery; Bo Qin; Yong Lin; Chi-Chen Hong; Christine B Ambrosone; Kitaw Demissie; Elisa V Bandera; Adana A M Llanos Journal: Environ Res Date: 2021-08-11 Impact factor: 6.498
Authors: Chato Taher; Jana de Boniface; Abdul-Aleem Mohammad; Piotr Religa; Johan Hartman; Koon-Chu Yaiw; Jan Frisell; Afsar Rahbar; Cecilia Söderberg-Naucler Journal: PLoS One Date: 2013-02-22 Impact factor: 3.240